HARRISBURG, PA, February 18, 2019 – MacuLogix,
Inc., the only company to equip eye care professionals with the instrument,
tools and education needed to effectively diagnose and treat patients with
age-related macular degeneration (AMD), relocated its headquarters from
Middletown to 3721 TecPort Drive, Ste 301, Harrisburg, PA 17111. The company
has grown from 12 to 65 employees in the past three years, including 25 home
office employees supporting its national field-based sales and customer success

“The 500% growth of our team is only outpaced
by the tremendous growth we’ve seen in sales during the past three years,” said
William D. McPhee, President and CEO of MacuLogix. “Designed to reflect our
roots as a medical technology start-up, our new headquarters provides a creative
and collaborative environment for our team and allows us to showcase our
sight-saving device. Plus, we have the option to further expand our footprint
as we continue to build the team to meet the growing demand for AdaptDx.”

quite humbling and exciting to see the company I co-founded more than a decade
ago experience such exponential growth in the past few years,” said Gregory R.
Jackson, PhD, Chief Technology Officer and Co-founder of MacuLogix. “Since our
initial funding was led by Pennsylvania-based Life Sciences Greenhouse
of Central Pennsylvania and Ben Franklin Technology Partners, we are very
proud to now be officially headquartered in the capital of our home state.”

The new MacuLogix headquarters occupies 17,400
square feet of space on the third floor of an office building it shares with
Aetna. Local designer Adrienne Shaver of Studio A Design Group worked closely
with the MacuLogix team to design a bright and welcoming environment to
accommodate their current and future needs.

About MacuLogix®

MacuLogix, Inc. equips eye
care professionals with the instrument, tools and education needed to
effectively diagnose and treat patients with AMD. By leveraging the science of
dark adaptation through its AdaptDx®, MacuLogix is working to eliminate
preventable blindness caused by AMD, a chronic, progressive disease that
impacts over 170 million people worldwide and goes undiagnosed in 25 percent of
patients. Through its AdaptDx® dark adaptation biomarker, MacuLogix enables eye
care professionals to detect, monitor and treat AMD three years before it can
be seen clinically. MacuLogix provides in-practice training and treatment best
practices to support the implementation and optimization of the AdaptDx®. Visit
www.maculogix.com for
additional information.

The post MacuLogix® Relocates to Larger Headquarters in Harrisburg, Pennsylvania to Accommodate Rapid Growth appeared first on Life Sciences Greenhouse of Central Pennsylvania.